An ATP-competitive inhibitor of human VEGFR1 and 2 and FGFR1 (IC50s = 380, 25, and 148 nM, respectively, for the human recombinant proteins); selective for VEGFR1 and 2 and FGFR1 over PDGFRβ, EGFR, LCK, PKCα, and JAK3 (IC50s = >1,900 nM; inhibits recombinant mouse Flk1 (IC50 = 89 nM); inhibits VEGF- and FGF-stimulated proliferation of HUVECs in vitro (IC50s = 40 and 276 nM, respectively); inhibits tumor growth by 85% and 97% when administered at 60 and 90 mg/kg p.o., respectively, for 10 days in an H3396 breast cancer mouse xenograft model; inhibits bile duct ligation-induced liver fibrosis in mice (25 mg/kg per day for 7 days, p.o.) and increases expression of PDGFβ, PDGFRβ, TGF-β1, TGF-β R2, FGF2, FGFR2, and VEGFR2 mRNAs